Leqembi (lecanemab-irmb) is a prescription drug that’s used to treat Alzheimer’s disease. Leqembi comes as a liquid solution that’s given as an intravenous (IV) infusion. A healthcare ...

Leqembi (lecanemab-irmb) has potential interactions with other medications. These interactions could cause harmful effects. An interaction can occur because one substance causes another substance ...

The tests add to the company’s existing PGx offerings for blood clotting, mental health, and immune suppression treatments.

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

Alzheimer’s disease gradually worsens over time, and there’s no cure for it yet. Leqembi (lecanemab) is a new type of medicine that can slow down how quickly Alzheimer’s disease gets worse.

U.S. health officials have endorsed the first blood test that can help diagnose Alzheimer’s. The test would help identify ...

The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test ...

Aaron is one of at least seven people who have died in the US from symptoms linked to the drug Leqembi over the past two years, according to a Bloomberg review of federal records obtained through ...

Viehbacher, “Biogen”) announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi ® (lecanemab) Marketing Authorization (MA) in the ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...

Lenvima sales are up solidly by around 10%, with Leqembi launching into its commercial phase now at 29.4 billion JPY cumulatively. Sequential performance has been solid. With a 42.5 billion JPY ...